CARSON CITY, Nev. - BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company, has announced positive findings from its clinical trials for the drug NE3107, aimed at treating symptoms of Parkinson's and Alzheimer's diseases. The results are set to be presented at the International Conference on Alzheimer's and Parkinson's Diseases 2024 in Lisbon, Portugal.
In a recent Phase 2a trial, Parkinson's Disease patients treated with NE3107, in addition to standard carbidopa/levodopa therapy, showed significant improvements in non-motor symptoms such as sleep/fatigue and motor control. The study found that NE3107-treated patients had a notable reduction in the Non-Motor Symptom Scale (NMSS) score, indicating less sleep/fatigue, compared to worsening symptoms in the placebo group.
Furthermore, the trial data revealed that NE3107 might enhance the effects of levodopa, a common Parkinson's treatment, particularly benefiting younger patients under 70. These findings suggest NE3107 could potentially improve both motor and non-motor symptoms of the disease, offering a new avenue for Parkinson's therapy.
For Alzheimer's Disease, a Phase 3 trial investigating NE3107 in mild to moderate cases showed promising, though not statistically significant, trends in cognitive and functional measures. Excluding data from sites with protocol violations, the remaining patient cohort displayed slower decline rates on several cognitive scales and improved metabolic and inflammatory biomarkers.
The trial's Principal Component Analysis indicated that NE3107 might realign physiological processes in a manner consistent with decreased neurocognitive decline. This hints at the potential for NE3107 to address underlying biological factors associated with Alzheimer's progression.
BioVie's research into NE3107 underscores the drug's potential to modify inflammation and insulin sensitivity in the brain, which could slow disease progression and improve patient outcomes. While further clinical investigation is necessary, these results contribute to the growing body of evidence supporting NE3107's therapeutic promise.
The company's focus remains on developing treatments for neurological and neurodegenerative disorders, as well as advanced liver disease. The information presented here is based on a press release statement from BioVie Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.